AIM: Early markers of response to chemotherapy, measured by blood markers and imaging, may ultimately lead to tailored therapies that avoid cumulative toxicity. MATERIALS & METHODS: We performed a small pilot study to compare early changes in levels of circulatory tumor cells (CTCs) with changes in tumor proliferation, using metabolic imaging with [(18)F] 3´-deoxy-3´-fluorothymidine PET (FLT-PET) in women with advanced breast cancer, before and during docetaxel therapy. RESULTS: In those individuals in whom we could detect CTCs, a decrease in CTC count correlated with a decrease in FLT-PET signal, within 2 weeks. CONCLUSION: Combined, these two technologies are likely to provide a powerful, albeit expensive, tool to assess immediate responses to therapy.
AIM: Early markers of response to chemotherapy, measured by blood markers and imaging, may ultimately lead to tailored therapies that avoid cumulative toxicity. MATERIALS & METHODS: We performed a small pilot study to compare early changes in levels of circulatory tumor cells (CTCs) with changes in tumor proliferation, using metabolic imaging with [(18)F] 3´-deoxy-3´-fluorothymidine PET (FLT-PET) in women with advanced breast cancer, before and during docetaxel therapy. RESULTS: In those individuals in whom we could detect CTCs, a decrease in CTC count correlated with a decrease in FLT-PET signal, within 2 weeks. CONCLUSION: Combined, these two technologies are likely to provide a powerful, albeit expensive, tool to assess immediate responses to therapy.
Authors: Lale Kostakoglu; Fenghai Duan; Michael O Idowu; Paul R Jolles; Harry D Bear; Mark Muzi; Jean Cormack; John P Muzi; Daniel A Pryma; Jennifer M Specht; Linda Hovanessian-Larsen; John Miliziano; Sharon Mallett; Anthony F Shields; David A Mankoff Journal: J Nucl Med Date: 2015-09-10 Impact factor: 10.057
Authors: Roberta Sala; Quang-Dé Nguyen; Chirag B K Patel; David Mann; Joachim H G Steinke; Ramon Vilar; Eric O Aboagye Journal: PLoS One Date: 2014-07-08 Impact factor: 3.240